Psychiatric medication-induced obesity: Treatment options

Obesity Reviews

Volumn 5, Issue 4, 2004, Pages 233-238

  Schwartz, T L ^a   Nihalani, N ^a   Virk, S ^a   Jindal, S ^a   Chilton, M ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Antidepressants; Antipsychotics; Obesity; Tolerability

Indexed keywords

AMANTADINE; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; CLOZAPINE; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METFORMIN; NALTREXONE; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PSYCHOTROPIC AGENT; QUETIAPINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ACIDOSIS; ATAXIA; BEHAVIOR THERAPY; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DIET THERAPY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EXERCISE; FATIGUE; GLAUCOMA; HUMAN; LIFESTYLE; MENTAL DISEASE; MORTALITY; OBESITY; REVIEW; SCHIZOPHRENIA; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DIET; HUMANS; LIFE STYLE; MENTAL DISORDERS; OBESITY; WEIGHT GAIN;

EID: 7044238388     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2004.00149.x     Document Type: Review

References (56)

1. Masand PS. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 2000; 1: 377-389.
2. Piji H, Meinders AE. Body weight changes as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996; 14: 329-342.
3. Dwyer DS, Ardizzone TD, Bradley RJ. Psychoactive drugs affect glucose transport and the regulation of glucose metabolism. Int Rev Neurobiol 2002; 51: 503-530.
4. Swift RM, Black HR. Essential hypertension: psychiatric aspects and use of psychotropics. Psychosomatics 1984; 25: 737-742.
5. Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intel Clin Pharm 1988; 22: 755-759.
6. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA. Comparison of Bupropion and Trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14: 170-179.
7. Chengappa RKN, Levine J, Rathore D, Parepally H, Atzert R. Long term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186-190.
8. Russell JM, Mackell JA. Body weight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-551.
9. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61: 37-41.
10. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240-244.
11. Harris T, Cook EF, Garrison R, Higgins M, Kannel W, Goldman L. Body mass index and mortality among nonsmoking older persons. The Framingham Heart Study. JAMA 1988; 259: 1520-1524.
12. Lee IM, Manson JE, Hennekens CH, Paffenburger RS. Body weight and mortality. A 27 year follow-up of middle-aged men. JAMA 1993; 270: 2823-2838.
13. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
14. Seidell JC, Verschuren WM, Vanleer EM, Kromhout D. Overweight, underweight and mortality. A prospective study of 48 287 men and women. Arch Intern Med 1996; 156: 958-963.
15. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.
16. Bender R, Jockel K-H, Trautner C, Spraul M, Berger M. Effect of age on excess mortality in obesity. JAMA 1999; 281: 1498-1504.
17. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
18. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62(Suppl. 23): 5-12.
19. AACE/ACE Obesity Task Force. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity. Endocr Pract 1998; 4: 297-350.
20. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
21. Weiss D. How to help your patients lose weight: current therapy for obesity. Cleve Clin J Med 2000; 67: 739-754.
22. Thomas PR, ed. Weighing the Options: Criteria for Evaluating Weight Management Programs/Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity, Food and Nutrition Board, Institute of Medicine. National Academy Press: Washington DC, 1995, 282 pp.
23. Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanisms of anovulation in hyperprolectinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril 1994; 62: 1143-1149.
24. Dorrington J, Gore-Langton I. Prolactin inhibits estrogen synthesis in the ovary. Nature 1981; 290: 600-602.
25. Leibowitz SF, Hoebel BG. Behavioral neuroscience of obesity. In: Bray GA, Bouchard C, James WPT (eds). Handbook of Obesity. M. Dekker: New York, NY, 1998, pp. 313-358.
26. Blackburn GL. Comparison of medically supervised and unsupervised approaches to weight loss and control. Ann Intern Med 1993; 119: 714-718.
27. Wadden TA. Evidence for success of calorie restriction in weight control; summary data from clinical research studies. In: Scannell SM (ed.). Methods for Voluntary Weight Loss and Control. Bethesda US Department of Health and Human Serv.: Bethesda, MD, 1992, pp. 64-74.
28. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999; 69: 198-204.
29. Greenburg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999; 60: 31-37.
30. Burstein R, Epstein Y, Shapiro Y, Charuzi I, Karnieli E. Effect of an acute bout of exercise on glucose disposal in human obesity. J Appl Physiol 1990; 69: 299-304.
31. Devlin JT, Horton ES. Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men. Diabetes 1985; 34: 973-979.
32. Kelley DE, Goodpaster BH. Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exerc 1999; 31: S619-S623.
33. Umbricht D, Flury H, Bridler R. Cognitive Behavior Therapy for weight gain. Am J Psychiatry 2001; 158: 971-972.
34. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley CM Jr. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170-1176.
35. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 227: 581-588.
36. Bray GA. Use and abuse of appetite suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119: 707-713.
37. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. Double-blind randomised controlled trial of sibutramine. Obes Res 1996; 4: 263-270.
38. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine-dose and long-term efficacy in weight loss, a double-blind study. Obes Res 1994; 18: 60-64.
39. Lean ME. Sibutramine: a review for clinical efficacy. Jnt J Obes Relat Metab Disord 1997; 21(Suppl. 1): S30-S36.
40. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight loss dose-ranging, efficacy study. J Clin Pharm Ther 1991; 50: 330-338.
41. Stock MJ. Sibutramine: a review of the pharmacology of an obesity agent. Int J Obes Relat Metab Disord 1997; 21(Suppl. 1): S25-S29.
42. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21: S12-S13.
43. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
44. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight gain in patients. Lancet 1998; 352: 167-172.
45. McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-249.
46. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 2-year randomised study. Diabetes Care 1998; 21: 1288-1294.
47. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996; 36: 152-159.
48. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in human volunteers. J Clin Pharmacol 1996; 36: 647-653.
49. Schwanz TL, Beale M. Psychotropic induced weight gain alleviated with orlistat. Psychopharmacol Bull 2003; 37: 5-8.
50. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11: 181-182.
51. Breier A, Tanaka Y, Roychowdhury S et al. Nizatidine for the Prevention of 'Weight Gain During Olanzapine Treatment in Schizophrenia and Related Disorders: a Randomised Controlled Double Blind Study. Presented at the Meeting of the Colleges of Psychiatric and Neurologic Pharmacists, 23-26 March 2001. San Antonio, TX, pp. 23-26.
52. Zimmermann U, Rechlin T, Plaskacewicz GJ, Barock A, Wildt L, Kaschka WP. Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Biol Psychiatry 1997; 41: 747-749.
53. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain. J Am Acad Child Adolesc Psychiatry 2001; 40: 1364.
54. Ghaemi SN, Manwani SG, Katzow JJ, Ko JY, Goodwin FK. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Ann Clin Psychiatry 2001; 13: 185-189.
55. Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, Cadevall J, Garcia-Castrillon J, Lusilla P, Arrufat F. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002; 22: 431-435.
56. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655-657.